MPR

FDA Approves Updated 2026-2027 COVID-19 Vaccines

FDA approves updated 2026-2027 COVID-19 vaccine formulations targeting the XFG variant for older adults and high-risk ...
MPR

Bixlenvo Approved as Single-Tablet Option in HIV-1 Management

A daily single-tablet combination of bictegravir and lenacapavir offers a simplified treatment option for virologically suppressed adults with HIV-1.
MPR

Mounjaro Approved to Reduce MACE Risk in Adults With T2DM

The FDA expanded tirzepatide's indication to include major adverse cardiovascular event reduction in adults with type 2 diabetes and established CV risk.
MPR

Lisraya Approved as First-in-Class Oral Dermatomyositis Treatment

Lisraya is the first oral dual TYK2/JAK1 inhibitor indicated for adults with dermatomyositis, demonstrating significant ...
MPR

Antenatal Complications Increased With Maternal Multiple Long-Term Conditions

The risk for antenatal complications is increased in association with maternal multiple long-term conditions (MLTCs), according to a study published in the Sept ...